Receipt of aromatase inhibitors was associated with risk of ischemic heart disease (HR = 1.52, 95% CI = 1.03–2.26 compared to patients without hormonal therapy), but not with risk of heart failure or arrhythmias (Table 3). The gene discussed is CYP19A1; the disease is cardiac arrhythmia.